Medixall Group, Inc.
Other OTCTotal Valuation
Medixall Group, Inc. carries a market capitalization of 1.15M, placing it among publicly traded companies globally. Its enterprise value stands at 663,126.30, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.15M |
| Enterprise Value | 663,126.30 |
Share Statistics
Medixall Group, Inc. currently has 138.90M shares outstanding.
| Shares Outstanding | 138.90M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.29, and the price-to-book ratio stands at 0.00.
| PE Ratio | N/A |
| PS Ratio | 0.29 |
| PB Ratio | 0.00 |
| P/TBV Ratio | -0.02 |
| P/FCF Ratio | -0.07 |
| P/OCF Ratio | -0.07 |
Enterprise Valuation
| EV / Sales | 2.18 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 0.46 |
Financial Position
Medixall Group, Inc. maintains a current ratio of 0.01, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -16.80, indicating conservative leverage, while an interest coverage ratio of -2.54 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | -16.80 |
| Debt / EBITDA | -0.30 |
| Interest Coverage | -2.54 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -640.47 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -1.43 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Medixall Group, Inc.'s stock has gained approximately 43.58974% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 43.58974% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Medixall Group, Inc. generated 304,336.00 in revenue and converted that into -2.16M in net income, yielding earnings per share of -0.01. EBITDA reached -2.05M, while operating income came in at -1.97M.
| Revenue | 304,336.00 |
| Gross Profit | 174,367.00 |
| Operating Income | -1.97M |
| Pretax Income | -2.16M |
| Net Income | -2.16M |
| EBITDA | -2.05M |
| EBIT | -1.97M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
Medixall Group, Inc. holds 31,916.00 in cash and equivalents against 607,925.00 in total debt, resulting in a net debt position of 558,307.00. Total book value stands at -38.82M, with working capital of -3.75M providing operational flexibility.
| Cash & Cash Equivalents | 31,916.00 |
| Total Debt | 607,925.00 |
| Net Debt | 558,307.00 |
| Equity (Book Value) | -38.82M |
| Book Value Per Share | -0.27 |
| Working Capital | -3.75M |
Cash Flow
Medixall Group, Inc. produced -1.20M in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.20M |
| Capital Expenditures | N/A |
| Free Cash Flow | -1.20M |
| FCF Per Share | -0.01 |
Margins
Medixall Group, Inc. operates with a gross margin of 57.29, reflecting its pricing power and cost economics. The operating margin of -645.91 and net profit margin of -710.77 provide insight into operational efficiency.
| Gross Margin | 57.29 |
| Operating Margin | -645.91 |
| Pretax Margin | -710.77 |
| Profit Margin | -710.77 |
| EBITDA Margin | -672.91 |
Dividends & Yields
The company's payout ratio of 11.02 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 11.02 |
| Shareholder Yield | -1,407.02 |
| FCF Yield | -1,381.46 |
Stock Splits
Medixall Group, Inc.'s most recent stock split took place on November 22, 2016 with a 15:1 split ratio.
| Last Split Date | 11/22/2016 |
| Split Ratio | 15:1 |
Scores
Medixall Group, Inc. posts an Altman Z-Score of -865.87, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -865.87 |